Labcorp Rides Regulatory Wins & Fights PAMA—Here’s How It’s Protecting Its Profits!

Labcorp Holdings reported its financial performance for the first quarter of 2025, reflecting a mixed set of outcomes amidst macroeconomic and regulatory dynamics. The company achieved solid revenue growth of 5.3%, reaching $3.3 billion, driven primarily by organic growth and strategic acquisitions. However, foreign currency translation exerted a slight negative pull on these figures. Diagnostics Laboratories saw growth, recovering after early-year weather disruptions, while Biopharma Laboratory Services (BLS) faced some challenges with slower growth, possibly due to ongoing regulatory uncertainties.